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Bailey Kessing5, Judith Hoffman-Bolton7, Lesley Francis1, Yin Yao Shugart8, Paul T. Strickland6,9,
W.H. Linda Kao6, Rhoda M. Alani10, Michael W. Smith11 and Anthony J. Alberg1,2,6
Nucleotide excision repair (NER) is responsible for protecting DNA in skin cells against UVR-induced damage.
Using a candidate pathway approach, a matched case–control study nested within a prospective, community-
based cohort was carried out to test the hypothesis that single-nucleotide polymorphisms (SNPs) in NER genes
are associated with susceptibility to non-melanoma skin cancer (NMSC). Histologically confirmed cases of
NMSC (n¼ 900) were matched to controls (n¼ 900) on the basis of age, gender, and skin type. Associations were
measured between NMSC and 221 SNPs in 26 NER genes. Using the additive model, two tightly linked functional
SNPs in ERCC6 were significantly associated with increased risk of NMSC: rs2228527 (odds ratio (OR) 1.57, 95%
confidence interval (CI) 1.20–2.05) and rs2228529 (OR 1.57, 95% CI 1.20–2.05). These associations were confined to
basal cell carcinoma (BCC) of the skin (rs2228529, OR 1.78, 95% CI 1.30–2.44; rs2228527, OR 1.78, 95% CI 1.31–2.43).
These hypothesis-generating findings suggest that functional variants in ERCC6 may be associated with an
increased risk of NMSC that may be specific to BCC.
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INTRODUCTION
Non-melanoma skin cancers (NMSC), mainly compris-
ing basal cell carcinomas (BCCs) and squamous cell
carcinomas (SCCs), are the most common malignancies
among Caucasians, with more than 2 million new cases
diagnosed in the United States each year (Rogers et al., 2010).
Risk of NMSC is largely determined by phenotypic char-
acteristics, such as skin pigmentation and ability to tan, in
combination with exposure to UVR (Armstrong and Kricker,
2001). UVR forms DNA photoproducts that can lead to
signature C-T or CC-TT mutations, the major genetic
lesion in NMSC (Kraemer, 1997).
The mechanism responsible for removing these lesions is
nucleotide excision repair (NER). The importance of NER in
the etiology of NMSC is clearly illustrated by xeroderma
pigmentosum (XP), a disease in which rare, highly penetrant
mutations disrupt the ability of NER to remove DNA
photoproducts, leading to a 1,000-fold increased risk of
NMSC (Kraemer et al., 2007; Rass and Reichrath, 2008). XP
can be caused by mutations in eight genes (XP complementa-
tion groups A–G and variant form), with some of these
mutations causing more severe skin cancer risk than others
(Cleaver, 1968; States et al., 1998). It thus stands to reason
that more common, but less penetrant, NER gene variants
may be associated with NMSC risk in the general population.
Studies of polymorphisms in NER genes have examined
their association with NMSC risk, with inconsistent findings
(Dybdahl et al., 1999; Vogel et al., 2001, 2005; Yin et al.,
2002; Han et al., 2005; Lovatt et al., 2005; Miller et al., 2006;
Applebaum et al., 2007). Many of these focused on only two
or three genes, and only functional single-nucleotide poly-
morphisms (SNPs), i.e., instances where variation in a single
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base pair in the DNA results in a different amino-acid upon
translation. As the NER pathway involves products from as
many as 31 different genes, a more thorough evaluation of
NER gene variants in relation to NMSC may provide a clearer
picture of the potential role of NER in NMSC. In addition,
progress is being made in the understanding of how the so-
called ‘‘silent’’ polymorphisms function, such as epigenetic
regulation of promoters (Esteller, 2008), pre-transcriptional
regulation via microRNA targeting of 30-untranslated regions
(Bartel, 2009), all the way through post-translational mod-
ification via synonymous polymorphisms in exons (Zhang
et al., 2010). Including markers from each of these regions
has advantages for characterizing the potential role of NER
gene variants in NMSC susceptibility. The fact that different
mutations in the same gene can lead to XP, Trichothiody-
strophy, and XP/Cockayne syndrome (CS)—three very differ-
ent clinical entities with marked differences in skin cancer
risk—further highlights why more thoroughly characterizing
NER gene variants is advantageous to better understand the
role of NER in NMSC (Kraemer et al., 2007). The present
candidate pathway association study was carried out to more
thoroughly examine the association between NER SNPs and
the risk of NMSC.
RESULTS
Cases and controls were similar with respect to gender and
skin type, but despite matching on age, cases were still an
average of 3.1 years older than controls (Po0.01) because
the pool of appropriate controls for the older age groups
tended to be at the lower end of the±5-year range (Table 1).
Cases were less likely than controls to have been current
smokers at baseline (Po0.01). Individuals with any BCC
were as likely to have had multiple lesions as those with any
SCC (34.5 vs. 38.8%, P¼0.21). Compared with men, women
were less likely to have had SCC (47.3 vs. 52.7%, P¼0.01),
and more likely to have had only one lesion (73.9 vs. 65.5%,
Po0.01).
The SNPs with Po0.05 for the additive model and their
associated odds ratios (ORs) for each genetic model,
adjusting for principal components, age, education, body
mass index, and smoking status, are presented in Table 2. The
top two SNPs were both functional polymorphisms in ERCC6:
Arg1213Gly (rs2228527) and Gln1413Arg (rs2228529). The
false discovery rate for these two SNPs was 12%. These two
SNPs were in tight linkage disequilibrium (r2¼0.97, D0 ¼ 1).
A third ERCC6 SNP, in an intron (rs4838518), also had
Po0.05.
The associations between the top hits from the primary
NMSC analyses were assessed separately for BCC and SCC.
The three ERCC6 SNPs were the top three most significantly
associated with BCC, but had null associations with SCC
(Table 3). For example, the ORs for BCC versus SCC in the
additive models were 1.78 (95% confidence interval (CI)
1.30–2.44) vs. 1.09 (95% CI 0.66–1.78) for rs2228529, 1.78
(95% CI 1.31–2.43) vs. 1.11 (95% CI 0.67–1.82) for
rs2228527, and 1.50 (95% CI 1.17–1.93) vs. 0.96 (95%CI
0.65–1.42) for rs4838518. Compared with 10,000 permuta-
tions for rs2228529, only two models were more significant
Table 1. Characteristics of NMSC cases and matched1
controls, Washington County, Maryland
Characteristic
NMSC cases (%)
(n=900)
Controls (%)
(n=900) P-value2
Age at baseline3
Mean±s.d. 59.7±13.0 56.6±13.1 o0.01
p34 4.4 5.9
35–44 9.4 13.8
45–54 18.4 19.7
55–64 27.7 31.0
65–74 27.6 24.0
X75 12.4 5.7
Gender
Male 46.3 46.3 1.0
Female 53.7 53.7
Education3
Mean±s.d. 12.1±3.0 12.4±2.9 0.48
o12 years 27.9 26.0
12 years 41.7 41.1
412 years 30.4 32.9
Body mass index3
Mean±s.d. 25.9±4.3 26.2±4.6 0.36
o18.5 1.3 0.8
18.5–24.9 42.9 41.8
25.0–29.9 41.0 40.2
X30.0 14.8 17.2
Cigarette smoking3
Never 51.1 43.0 o0.01
Former 35.0 30.7
Current 13.9 26.3
Skin type4
Blistering burn 14.5 14.5 0.89
Burn without blisters 34.0 31.6
Burn that tans 38.0 40.4
Tan without burn 10.2 10.9
No change 3.3 2.6
Missing (n=479) (n=479)
Basal cell carcinoma
1 65.5 —
41 34.5 —
Squamous cell carcinoma
1 61.2 —
41 38.8 —
Abbreviation: NMSC, non-melanoma skin cancer.
1Controls were matched on age (±5 years, ±10 years for those X75),
gender, and skin type. In all, 13 cases were matched to controls whose
skin type was off by one category.
2w2 test.
3Measured at baseline in 1989.
4Measured in 2003 and 2007.
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than 0.0003, whereas no point estimate was 41.70,
compared with the observed 1.78. The only SNP significantly
associated with SCC was rs17495770 (P¼ 0.0475).
The analyses subsequently focused on characterizing the
associations between the ERCC6 SNPs and skin cancer risk;
given the heterogeneity in the associations between these
SNPs for BCC and SCC, these analyses were additionally
stratified by histological type. To further investigate the
finding that multiple SNPs from the same gene met the
screening criteria of Po0.05, haplotypes were constructed
from the unphased data for the three ERCC6 SNPs. After
adjusting for the same variables described above, the overall
haplotype test for NMSC was significant (P¼ 0.03), with the
GAG haplotype (rs2228529, rs4838518, rs2228527), which
contained the minor allele for all three SNPs, associated with
increased risk of NMSC compared with the AGA haplotype
(OR 1.63, 95% CI 1.23–2.16) (Table 4). In analyses stratified
by histological type, the overall haplotype test was significant
for BCC (Po0.01) but not SCC (P¼ 0.99). For BCC, compared
with the haplotype of all wild-type alleles (AGA), the
haplotype with three variant alleles was associated with
increased risk (GAG OR 1.94, 95% CI 1.40–2.67, Po0.0001)
(Table 4). Of the 281 confirmed cases of SCC, there were 90
cases who also had a confirmed diagnosis of BCC. In the 191
cases with no BCC, the association between rs2228529 and
SCC was OR 1.06, 95% CI 0.58–1.92, P¼ 0.85. In the 90
cases with confirmed BCC and SCC, the OR was 1.66 (95%
CI 0.54–5.11, P¼ 0.37), more closely approximating that for
BCC.
The two ERCC6 functional polymorphisms, rs2228527
and rs2228529, were significantly associated with NMSC
among both men and women (Table 5). The risks associated
with these two SNPs increased for multiple lesions. For
rs2228527, the OR was 1.43 (95% CI 1.05–1.94) for a single
lesion and 2.16 (95% CI 1.19–3.92) for multiple lesions; the
corresponding figures for rs2228529 were 1.42 (1.04–1.93)
and 2.24 (1.23–4.10) (Table 5). For SCC, the ORs for both
ERCC6 SNPs, although not significant, were in the direction
of increased risk among men, but decreased risk among
women (Table 5). This gender difference remained after
excluding those with both BCC and SCC, indicating that it
was not driven by association with BCC.
Table 2. SNPs associated with NMSC at Po0.05 using the additive model
SNP Gene MAF
Genotype
(case/control)1 HWE P P-value2
Additive OR
(95% CI)
Genotype OR
(95% CI)
Dominant OR
(95% CI)
Recessive OR
(95% CI)
rs2228527 ERCC6 Arg1213Gly 0.1983 AA (568/600)
AG (283/264)
GG (48/35)
0.3781 0.0007 1.57 (1.20–2.05) AA: 1.0 (referent)
AG: 1.65 (1.18–2.31)
GG: 2.17 (1.06–4.46)
1.71 (1.23–2.37) 1.80 (0.89–3.62)
rs2228529 ERCC6 Gln1413Arg 0.2013 AA (563/592)
AG (290/272)
GG (47/34)
0.6646 0.0008 1.57 (1.20–2.05) AA: 1.0 (referent)
AG: 1.62 (1.16–2.27)
GG: 2.26 (1.08–4.72)
1.69 (1.22–2.33) 1.88 (0.92–3.85)
rs17495770 RPA3
intron (LOC729852)
0.1403 GG (645/682)
CG (233/208)
CC (22/10)
0.2272 0.0017 1.68 (1.21–2.34) GG: 1.0 (referent)
CG: 1.65 (1.14–2.39)
CC: 3.13 0.86–11.40)
1.71 (1.19–2.45) 2.74 (0.76–9.87)
rs4647709 DDB2
intron
0.0853 GG (768/736)
AG (127/158)
AA (5/6)
0.5589 0.0066 0.59 (0.40–0.87) GG: 1.0 (referent)
AG: 0.54 (0.36–0.81)
AA: 1.61
(0.19–14.01)
0.55 (0.37–0.83) 1.57 (0.19–13.40)
rs4134822 XAB2/XPA Val126Ile 0.01426 GG (858/879)
AG (34/17)
AA (0/0)
1 0.0186 2.69 (1.13–6.40) GG: 1.0 (referent)
AG: 2.69 (1.13–6.40)
AA: —
2.69 (1.13–6.40) —
rs4150530 GTF2H1 50-UTR 0.1042 CC (737/706)
AC (155/182)
AA (7/12)
0.8702 0.0334 0.67 (0.47–0.97) CC: 1.0 (referent)
AC: 0.66 (0.44–0.99)
AA: 0.52 (0.11–2.33)
0.65 (0.44–0.96) 0.56 (0.13–2.52)
rs4838518 ERCC6
intron
0.485 GG (237/245)
AG (438/451)
AA (224/204)
0.9467 0.0329 1.26 (1.02–1.57) GG: 1.0 (referent)
AG: 1.10 (0.77–1.57)
AA: 1.62 (1.05–2.48)
1.24 (0.89–1.73) 1.52 (1.06–2.17)
rs876430 ERCC5 flanking 0.2626 GG (467/505)
AG (372/337)
AA (61/57)
0.9294 0.0313 1.31 (1.02–1.67) GG: 1.0 (referent)
AG: 1.24 (0.89–1.73)
AA: 1.85 (1.02–3.38)
1.33 (0.97–1.82) 1.70 (0.95–3.06)
rs1264302 VARS2 synonymous
(GTF2H4)
0.3598 GG (354/376)
AG (420/421)
AA (124/102)
0.3774 0.0347 1.27 (1.02–1.59) GG: 1.0 (referent)
AG: 1.22 (0.88–1.69)
AA: 1.66 (1.03–2.67)
1.31 (0.96–1.78) 1.48 (0.96–2.30)
Abbreviations: CI, confidence interval; HWE, Hardy–Weinberg equilibrium; MAF, minor allele fraction; NMSC, non-melanoma skin cancer; OR, odds ratio;
SNP, single-nucleotide polymorphism; UTR, untranslated region.
All models are adjusted for the first three principal components, and baseline age, education, body mass index, and smoking status.
1Numbers do not add up to 1,800 owing to genotyping failures.
2Permutation P-value from the additive model.
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DISCUSSION
In a community-based study, after matching for age, gender,
and skin type, a thorough evaluation of NER gene variants
revealed associations between two functional ERCC6 SNPs
and NMSC, which to our knowledge have not been
previously reported. These two SNPs, rs2228527 and
rs2228529, had minor allele frequencies of 20%, and the
associations were compatible with increased NMSC risks of
1.6-fold for heterozygotes and 2.2-fold for those with the
homozygous variant genotype. The increased risk was
consistent among both men and women and increased in
strength with increasing number of lesions. Individuals with
NMSC will commonly develop multiple primary tumors
during their lifetime. For example, the 3-year risk of
developing BCC after an initial SCC is as high as 43%,
whereas studies indicate that the 3-year risk of developing
SCC after BCC ranges from 1 to 19% (Marcil and Stern,
2000). Both ERCC6 SNPs were associated with increased risk
of NMSC that grew stronger with an increasing number of
lesions, a trend that was most pronounced among individuals
with a history of BCC. Furthermore, the associations were
specific to BCC.
Table 3. For the top SNPs associated with NMSC, the ORs (and 95% CIs and P-values) of each SNP with BCC
and SCC
BCC (n=701 cases) SCC (n=281 cases)
SNP Gene P-value1
Frequency of
case/control2
Additive OR
(95% CI)
Genotype OR
(95% CI) P-value1
Frequency of
case/control2
Additive OR
(95% CI)
Genotype OR
(95% CI)
rs2228529 ERCC6 Gln1413Arg 0.0003 AA (436/463)
AG (230/210)
GG (35/27)
1.78 (1.30–2.44) AA: 1.0 (referent)
AG: 1.90
(1.28–2.80)
GG: 2.78
(1.22–6.33)
0.7481 AA (175/182)
AG (87/87)
GG (19/11)
1.09 (0.66–1.78) AA: 1.0 (referent)
AG: 1.02
(0.56–1.87)
GG: 1.42
(0.33–6.14)
rs2228527 ERCC6 Arg1213Gly 0.0003 AA (440/469)
AG (224/204)
GG (36/28)
1.78 (1.31–2.43) AA: 1.0 (referent)
AG: 1.94
(1.31–2.88)
GG: 2.67
(1.20–5.93)
0.6908 AA (178/186)
AG (84/83)
GG (19/11)
1.11 (0.67–1.82) AA: 1.0 (referent)
AG: 1.05
(0.57–1.94)
GG: 1.43
(0.33–6.15)
rs4838518 ERCC6
intron
0.0016 GG (177/195)
AG (344/352)
AA (179/154)
1.50 (1.17–1.93) GG: 1.0 (referent)
AG: 1.42
(0.93–2.15)
AA: 2.26
(1.36–3.75)
0.8333 GG (79/74)
AG (130/141)
AA (72/66)
0.96 (0.65–1.42) GG: 1.0 (referent)
AG: 0.62
(0.32–1.22)
AA: 0.97
(0.44–2.16)
rs17495770 LOC729852 (RPA3) 0.0166 GG (502/523)
CG (177/168)
CC (22/10)
1.56 (1.08–2.23) GG: 1.0 (referent)
CG: 1.50
(0.99–2.26)
CC: 2.94
(0.82 –10.57)
0.0475 GG (201/215)
CG (77/66)
CC (3/0)
2.10 (1.01–4.37) GG: 1.0 (referent)
CG: 2.03
(0.97–4.26)
CC: —
rs4647709 DDB2
intron
0.0203 GG (591/566)
AG (105/131)
AA (5/4)
0.61 (0.40–0.93) GG: 1.0 (referent)
AG: 0.54
(0.34–0.84)
AA: 1.99
(0.20 –19.41)
0.0820 GG (241/238)
AG (39/41)
AA (1/2)
0.49 (0.22–1.10) GG: 1.0 (referent)
AG: 0.47
(0.20–1.08)
AA: 0.93
(0.00–847.3)
rs1264302 VARS2
synonymous
0.0256 GG (274/303)
AG (324/317)
AA (102/81)
1.33 (1.04–1.71) GG: 1.0 (referent)
AG: 1.37
(0.93–2.00)
AA: 1.74
(1.03–2.94)
0.1710 GG (116/121)
AG (131/132)
AA (33/27)
1.38 (0.87–2.19) GG: 1.0 (referent)
AG: 1.24
(0.67–2.28)
AA: 2.15
(0.77–5.98)
rs4134822 XAB2/XPA Val126Ile 0.0366 GG (667/684)
AG (28/13)
AA (0/0)
2.83 (1.07–7.49) GG: 1.0 (referent)
AG: 2.83
(1.07–7.49)
AA: —
0.2510 GG (267/273)
AG (11/7)
AA (0/0)
2.32 (0.55–9.80) GG: 1.0 (referent)
AG: 2.32
(0.55–9.80)
AA: —
rs4150530 GTF2H1
50-UTR
0.0730 CC (574/554)
AC (121/140)
AA (6/7)
0.68 (0.45–1.04) CC: 1.0 (referent)
AC: 0.66
(0.42–1.04)
AA: 0.62
(0.11–3.56)
0.3240 CC (227/212)
AC (51/63)
AA (2/6)
0.73 (0.39–1.37) CC: 1.0 (referent)
AC: 0.79
(0.40–1.57)
AA: 0.18
(0.00–7.42)
rs876430 ERCC5
flanking
0.0824 GG (362/390)
AG (293/264)
AA (46/46)
1.28 (0.97–1.69) GG: 1.0 (referent)
AG: 1.30
(0.89–1.89)
AA: 1.59
(0.81–3.13)
0.1849 GG (150/157)
AG (107/109)
AA (24/15)
1.38 (0.86–2.23) GG: 1.0 (referent)
AG: 0.97
(0.51–1.85)
AA: 3.62
(1.05–12.51)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HWE, Hardy–Weinberg equilibrium; MAF, minor allele fraction; NMSC, non-melanoma
skin cancer; OR, odds ratio; SCC, squamous cell carcinoma; SNP, single-nucleotide polymorphism; UTR, untranslated region.
All models are adjusted for the first three principal components, and baseline age, education, body mass index, and smoking status.
1P-value from the additive model.
2Numbers of cases and controls with each genotype. Numbers do not add up to 1,402 for BCC or 562 for SCC owing to genotyping failures.
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To our knowledge, no previous evidence has been
reported on the association between either rs2228527 or
rs2228529 and NMSC. Several genome-wide association
studies of NMSC have been conducted, and thus the fact that
the results for these two SNPs have yet to be reported
indicates that they were not among the most significant
SNPs (Gudbjartsson et al., 2008; Stacey et al., 2008, 2009;
Rafnar et al., 2009; Nan et al., 2011; Zhang et al., 2011a, b).
In studies based in Iceland, the association between risk of
NMSC and SNPs that were associated with pigmentation
within this study population (Gudbjartsson et al., 2008),
and the most significant 35 SNPs from a genome-wide scan
have been reported (Stacey et al., 2008, 2009; Rafnar et al.,
2009). Similarly, a genome-wide association study using
Table 4. ORs (and 95% CIs) of NMSC, BCC, and SCC according to ERCC6 haplotype (rs2228527, rs4838518,
rs2228529)
Haplotype
Frequency of
case/control
NMSC OR
(95% CI)
Frequency of
BCC cases
BCC OR
(95% CI)
Frequency
of SCC cases
SCC OR
(95% CI)
AGA 50.3/52.0 1.0 (referent) 49.3 1.0 (referent) 50.7 1.00 (referent)
AAA 28.2/29.0 1.11 (0.87–1.41) 29.0 1.24 (0.94–1.63) 27.1 0.94 (0.59–1.49)
AAG 0.1/0.1 1.28 (0.09–17.73) 0.1 1.60 (0.12–21.80) 0 —
GGA 0.4/0.3 1.88 (0.35–10.14) 0.4 2.08 (0.35–12.28) 0.5 0.71 (0.05–10.74)
GAG 20.9/18.5 1.63 (1.23–2.16) 21.0 1.94 (1.40–2.67) 21.7 1.07 (0.64–1.80)
Overall P-value 0.03 o0.01 0.99
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; NMSC, non-melanoma skin cancer; OR, odds ratio; SCC, squamous cell carcinoma.
All models were adjusted for the first three principal components, and baseline age, education, body mass index, and smoking.
Six of the possible eight haplotypes were observed, with one occurring only among controls (GAA, n=2).
Numbers do not add up to 100 owing to rounding.
Table 5. For the top two ERCC6 SNPs associated with NMSC, ORs (and 95% CIs) of NMSC, BCC, and SCC, and
stratified according to sex and number of lesions
NMSC BCC SCC
ERCC6 SNP n cases/controls OR (95% CI) n cases/controls OR (95% CI) n cases/controls OR (95% CI)
rs2228527 899/899 1.57 (1.20–2.05) 700/700 1.78 (1.31–2.43) 280/280 1.11 (0.67–1.82)
Sex
Males 417/417 1.78 (1.07–2.97) 317/317 1.78 (0.88–3.57) 148/148 1.74 (0.72–4.20)
Females 482/482 1.41 (1.03–1.95) 383/383 1.68 (1.13–2.48) 132/132 0.87 (0.45–1.65)
No. of lesions
None 899 1.0 (referent) 700 1.0 (referent) 280 1.0 (referent)
1 629 1.43 (1.05–1.94) 458 1.72 (1.19–2.48) 171 0.92 (0.50–1.70)
41 270 2.16 (1.19–3.92) 242 2.07 (1.12–3.80) 109 1.70 (0.59–4.86)
rs2228529 898/898 1.57 (1.20–2.05) 700/700 1.78 (1.30–2.44) 280/280 1.09 (0.66–1.78)
Sex
Males 416/416 1.75 (1.04–2.94) 316/316 1.88 (0.92–3.86) 148/148 1.67 (0.69–4.01)
Females 482/482 1.42 (1.03–1.96) 384/384 1.70 (1.15–2.52) 132/132 0.86 (0.45–1.64)
No. of lesions
None 898 1.0 (referent) 700 1.0 (referent) 280 1.0 (referent)
1 628 1.42 (1.04–1.93) 458 1.70 (1.17–2.47) 171 0.93 (0.50–1.72)
41 270 2.24 (1.23–4.10) 242 2.15 (1.16–3.99) 109 1.73 (0.60–4.99)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; NMSC, non-melanoma skin cancer; OR, odds ratio; SCC, squamous cell carcinoma; SNP,
single-nucleotide polymorphism.
Numbers do not add up to 1,800 owing to genotyping failures.
ORs and 95% CIs are from the additive model, adjusted for the first three principal components, age at baseline, education, body mass index, and smoking
status.
Both BCC and SCC may be present among those with 41 lesion.
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the Nurses’ Health Study and the Health Professionals
Follow-up Study has reported the most significant SNPs
overall (Nan et al., 2011), as well as select SNPs from within
two Kyoto Encyclopedia of Genes and Genomes pathways
shown to be enriched for significant associations (Zhang
et al., 2011a, b); for the latter, the NER pathway was not
significant for enrichment (P¼ 0.33), but the associations
for individual genes and SNPs were not presented (Zhang
et al., 2011b). There were also important between-
study differences in case definition. This study comprised
histologically confirmed NMSC cases whose NMSC was
not preceded by any other cancer; the Icelandic cohort
included histologically confirmed BCC cases regardless
of other cancer diagnoses; and the Nurses’ Health
Study/Health Professionals Follow-up Study included self-
reported BCC that was the patient’s only known cancer,
excluding those with both BCC and SCC. The SNPs
identified in this study could possibly be associated with
NMSC in these genome-wide association studies, but did
not reach the stringent genome-wide association study
significance threshold.
The rs2228529 SNP falls within a highly conserved
ubiquitin-binding domain in ERCC6 that is necessary for the
transcription-coupled repair branch of NER (Anindya et al.,
2010). The function of rs2228527 is currently unknown,
although its observed association with NMSC in this study
could be due solely to its tight linkage with rs2228529.
ERCC6, also called CSB, is mutated in CS, which presents as
progressive sensorineural degeneration and sun sensitivity.
CS patients are not reported to have an increased risk of
NMSC (Kraemer et al., 2007); however, the average lifespan
of individuals with CS is only 12 years, and thus they may not
survive long enough for an increased NMSC risk to manifest
(Hoeijmakers, 2009). Alternatively, the global genome repair
branch of NER may compensate for a defective ERCC6 in CS,
as suggested by mouse models, and attenuate NMSC risk (van
der Horst et al., 1997; Nouspikel, 2009; Tornaletti, 2009;
Pines et al., 2010). Knockdown of ERCC6 in human
keratinocytes decreased repair of UV-induced cyclobutane
dimers, as well as 8-oxo-deoxyguanine, providing mechan-
istic evidence of a role for ERCC6 in skin carcinogenesis
(Javeri et al., 2011). In the absence of a larger-scale,
hypothesis-driven study such as this study, an increased risk
of NMSC associated with ERCC6, if true, may not have been
detected.
In this study, nonsignificant increased risks of NMSC were
observed for rs13181 (OR 1.10, 95% CI 0.88–1.37,
P¼0.3975) and rs1800975 (OR 1.15, 95% CI 0.92–1.44,
P¼0.2328). Because of a low genotyping platform design
score, rs1799793 was not genotyped. Many studies have
measured the association between these three XPD and XPA
polymorphisms and NMSC (Dybdahl et al., 1999; Vogel
et al., 2001, 2005; Yin et al., 2002; Han et al., 2005; Lovatt
et al., 2005; Miller et al., 2006; Applebaum et al., 2007). The
largest of these, drawing from a population-based study in
New Hampshire with nearly 900 cases of BCC and 700 of
SCC, observed a 15–25% decreased risk of either BCC or SCC
among those with the XPA A23G (rs1800975) polymorphism
(Miller et al., 2006), as well as a 20% decreased risk of SCC
and 10% decreased risk of BCC among those carrying variant
forms of both XPD Lys751Gln and Asp312Asn (Applebaum
et al., 2007), after adjusting for age, sex, skin pigmentation,
and number of severe sunburns. There was a significant
30–40% reduced risk of SCC among carriers of the XPD
Lys751Gln (rs13181) variant in the Nurses Health Study
(n¼286 SCC cases, n¼874 controls), and a roughly 20%
decreased risk for XPD Asp312Asn (rs1799793), whereas
neither was associated with BCC (n¼ 300 cases), adjusting
for age, race, skin type, sunburns, family history, geography,
tanning bed use, and sun exposures (Han et al., 2005). Some
studies support a nonsignificantly decreased risk of NMSC
associated with these variants (Lovatt et al., 2005; Vogel
et al., 2005), whereas others have found nonsignificant
increases in risk (Vogel et al., 2001, 2005; Yin et al., 2002).
In general, more of the NER SNPs associated with NMSC
were associated with BCC than SCC, adding supportive
evidence to the hypothesis that risk of BCC and SCC may be
associated with differentNER genes and pathophysiology. For
example, XP patients with mutations in XPC are known to
have a preponderance of SCCs (Kraemer et al., 2007). In this
study, no SNPs in XPC were associated with the risk of either
BCC or SCC. However, in the majority of UVR-induced SCCs,
XPC expression is lost (de Feraudy et al., 2010a, b), and this
inactivation has been shown to be sufficient for neoplastic
transformation (Rezvani et al., 2011). Therefore, individuals
with SCC could possibly have an XP phenotype acquired
through somatic mutation that was not measured in this study
of germline SNPs, potentially contributing to the weaker
associations for SCC than BCC.
The strengths of this study include its community-based
study design, matching on important NMSC risk factors, its
broad coverage of the NER pathway, and its sample size of
histologically confirmed cases of NMSC comparable to the
largest studies addressing this question. Skin type is the
strongest phenotypic predictor of skin cancer risk, and is also
correlated with sun exposures in this population, suggesting
that there was also some control for environmental sun
exposures (Wheless et al., 2009). The associations with
NMSC for those missing skin type data (rs2228529, OR 1.80,
95% CI 1.18–2.74; rs2228527, OR 1.78, 95% CI 1.17–2.72)
were stronger than those who had skin type data (rs2228529,
OR 1.49, 95% CI 1.03–2.15; rs2228527, OR 1.51, 95% CI
1.05–2.18), indicating that there may be residual confounding
among those who were matched on the ‘‘missing’’ category
for skin type. Although 450% of the study population was
missing skin type data, both ERCC6 SNPs still had ORs41.0
and Po0.05 upon stratification by those with and without
skin type data, suggesting that the missing data did not impact
the overall conclusion of increased risk associated with these
two SNPs.
A number of limitations should be kept in mind when
drawing inferences from this study. Despite a rigorous
matching protocol, residual case–control age differences
remained. In analyses stratified according to age o65 versus
±65 years at baseline, the ERCC6 functional variants were
significant (Po0.05) within both age groups (data not shown).
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Moreover, the median age of diagnosis for cases was 64 years
(mean 63.4±13.0, range 22–93), an age the controls
surpassed on average midway through the follow-up period
without developing NMSC. As such, the age difference
between cases and matched controls most likely did not
substantially bias the results. The age difference also led to
the exclusion of more than 100 cases for which there were no
appropriate controls. The allele frequencies for the two
ERCC6 functional polymorphisms among these excluded
cases were no different than among the included cases of the
same age group (rs2228527, P¼0.95; rs2228529, P¼0.91),
suggesting that these exclusions likely did not impact the
overall associations. With regard to the number of NMSCs,
those categorized as having multiple lesions are confirmed to
have had more than one NMSC. The follow-up was
incomplete, and thus some individuals classified with one
lesion may in fact have had more than one, as individuals
with a previous NMSC are at a greatly increased risk of
developing additional lesions (Marcil and Stern, 2000). To
the extent this was true, it would have biased against
detecting a trend in risk with the number of lesions, and thus
the estimates of the trend in this study are likely conservative.
Sunburns are markers of acute, intermittent sun exposure,
the pattern most strongly associated with BCC (Armstrong
and Kricker, 2001). Data from the 2007 follow-up ques-
tionnaire concerning blistering sunburns (ever vs. never) were
available for 142 matched case–control sets. In this subset,
the associations between rs2228529 and NMSC and BCC
actually increased slightly after adjusting for history of
blistering sunburns, although the confidence intervals were
wide (data not shown). These results, although limited by
being from a small, potentially highly selected sample,
suggest that further adjusting for sunburn history is unlikely
to attenuate the observed association between the ERCC6
SNPs and BCC.
The strength and internal consistency of the associations
between these functional SNPs and NMSC in this study
suggest that a closer examination of these SNPs is warranted.
Only two of 10,000 permutations for rs2228529 were more
significant than the observed P-value, and no permutations
had ORs as strong as the observed ORs, making it highly
unlikely that these findings were due to chance. The findings
that two nonsynonymous coding SNPs in ERCC6 are
associated with NMSC, and perhaps specifically to BCC,
have to our knowledge not been previously reported. Before
these findings can be assessed for public health or clinical
relevance, they will first need to be replicated and functional
significance established to clarify the role of ERCC6 in
NMSC. If these associations prove to be genuine in the long
run, they will advance understanding of skin carcinogenesis
and could be of potential relevance to risk stratification and
targeting preventive measures.
The results of this study suggest that two functional
polymorphisms in ERCC6 may have a role in the risk of
NMSC, especially BCC. Although known for its causative role
in CS, previously ERCC6 has been associated with the risk of
skin cancer in mice, but not humans. Using a candidate
pathway–based approach, combined with a methodologically
sound population-based, matched case–control study, the
results identify ERCC6 as a new target for study as a potential
skin cancer risk factor.
MATERIALS AND METHODS
Study population
This study was approved by the Institutional Review Boards of the
Johns Hopkins University Bloomberg School of Public Health and
the Medical University of South Carolina and was conducted
according to Declaration of Helsinki Principles, including written
informed consent. This case–control study was nested within the
larger parent study, the ‘‘Give Us a Clue to Cancer and Heart
Disease’’ (CLUE II) study, established in 1989 in Washington
County, Maryland. At baseline, participants provided demographic
information and gave a 20-ml blood sample that was collected in a
heparinized 20-ml vacutainer tube. All blood samples were
immediately refrigerated until centrifugation, which usually took
place within 6 h and never exceeded 24 h. Aliquots of plasma, red
blood cells, and buffy coats were then separated and stored at
70 1C.
The NMSC cases were ascertained through linkage with the
Washington County Cancer Registry, which registers NMSC
diagnoses. The follow-up period concluded on 31 December 2008.
Selection of cases and controls
From the 28,594 individuals who at baseline had no history of
cancer other than NMSC, a subset of 6,589 individuals was selected
for genotyping, including 1,391 histologically confirmed incident
cases of NMSC and 2,586 cancer-free controls. The remaining
individuals in the genotyping cohort had cancers other than NMSC,
and thus were not included in this study. Of the NMSC cases and
cancer-free controls, genotyping was never attempted because of
DNA quality or availability in n¼ 212 individuals; n¼ 132 were
excluded because of low genotyping rates; and an additional n¼ 64
were excluded on the basis of principal components analysis
clustering by genetic ancestry. This latter exclusion was to minimize
the potential for population stratification by genetic admixture.
Finally, 242 cases were excluded based on diagnosis of another
cancer before diagnosis of NMSC, as the NMSC potentially could
have been caused by treatment-related factors (Perkins et al., 2005).
After these exclusions, this left a total of 1,027 cases and 2,300
cancer-free controls available for matching. Cases and controls were
matched on age ±5 years (±10 years for those 75 and older),
gender, and skin type. Race and ethnicity were accounted for in the
initial principal components analysis of genetic ancestry by
restricting to a single, genetically homogeneous cluster. Moreover,
the entire cohort was almost exclusively Caucasian of northern
European descent.
On the basis of this protocol, 887 cases were matched to 887
controls. An additional 13 cases were matched to controls whose
skin type was off by one category, bringing the total to 900 in both
groups. The majority of cases who were excluded because of the
lack of a suitable matching control were men aged 65 years and
older (n¼ 92).
NER genotyping
From a larger study examining SNPs from all DNA repair
mechanisms as a potential explanation for the increased risk of
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second primary cancers after NMSC (Jorgensen et al., 2009), this
study focuses on the association between NER pathway SNPs and
NMSC. A complete description of the selection of genes and SNPs
analyzed in the parent study was previously reported (Jorgensen
et al., 2009). Briefly, the SNP selection strategy was to (1) identify all
known NER genes, (2) select all validated functional SNPs, i.e., those
that change the amino-acid sequence of the protein product, and
(3) select tagging SNPs to obtain as complete coverage as possible.
Using this method, 347 SNPs in 28 genes of the NER pathway were
selected.
Genotyping was performed at the Laboratory of Genomic
Diversity at the National Cancer Institute using the Illumina Golden
Gate assay with a custom-designed microarray chip.
After excluding SNPs due to genotyping failure (o95% success,
n¼ 28), deviation from Hardy–Weinberg equilibrium (Po0.001,
n¼ 33), or low minor allele frequency (o0.01, n¼ 65), 221 SNPs in
26 genes remained for analyses. A complete listing of the RefSNP (rs)
number, gene, and P-value for the association with NMSC is
provided in Supplemental Table S1 online.
Covariate information
Demographic information collected at baseline included age, self-
reported race, gender, years of education, body mass index, and
smoking history. Follow-up questionnaires were periodically mailed
to participants, with those in 2003 and 2007 containing items
relevant to skin cancer, including skin type and sun exposure. The
questionnaire concerning the skin type variable that was used in the
matching protocol was included in both 2003 and 2007 and asked,
‘‘If you spent an hour in the midday sun for the first time without
sunscreen, which of these reactions best describes what would
happen to your skin?’’. The five possible responses were as follows:
‘‘blistering sunburn,’’ ‘‘sunburn without blisters,’’ ‘‘mild sunburn that
becomes a tan,’’ ‘‘tan or darken with no sunburn,’’ or ‘‘no change in
skin color.’’ As tanning ability tends to decrease with age (Gilchrest
et al., 1979), the response from the 2003 survey was used to
determine skin type, except when there was no response in 2003, in
which case the 2007 data were used.
Statistical analysis
Genetic heterogeneity was assessed using principal components in
the statistical environment R (R Project, www.r-project.org).
Comparison with the three HapMap2 populations identified subjects
of non-Caucasian background (largely identical to self-reported race,
data not shown). To avoid potential population stratification among
the Caucasians, the first three principal components were recorded
and used in the data analyses.
Hardy–Weinberg equilibrium was assessed among the controls
using PLINK v.1.07 (Shaun Purcell, http://pngu.mgh.harvard.edu/
purcell/plink/; Purcell et al., 2007). A two-step strategy was used to
assess the association between NER SNPs and NMSC. First, a macro
in SAS version 9.1 (SAS Institute, Cary, North Carolina) was used to
screen each SNP for its association with NMSC using the additive
genetic model in a conditional logistic regression, which is on a
multiplicative scale. In the additive model, each individual is coded
as having 0, 1, or 2 copies of the minor allele for each SNP (Sasieni,
1997). The covariates adjusted for in these models were the first
three principal components from the population stratification
analysis, and baseline age (continuous), education (o12 years, 12
years, 412 years), body mass index (body mass index, continuous),
and smoking (never, former, current). Second, for SNPs with additive
genetic model Po0.05, the mode of inheritance (dominant,
recessive, or genotype) was assessed. Conditional logistic regression
was used to calculate ORs and 95% CIs.
Ancillary analyses examined differences between histology (BCC
vs. SCC), number of NMSCs (0, 1,41), and gender. The haplotypes
were constructed from unphased markers using PLINK, with
subsequent conditional regression analyses conducted in SAS.
Unless otherwise specified, SAS was used for all analyses. The
Bonferroni correction does not account for the reality that in this
study some of the genotyped SNPs were in high linkage disequili-
brium, which would make this test overly conservative. Therefore, to
account for the actual linkage disequilibrium present among the
SNPs genotyped, empirical significance levels for the top SNPs were
generated using 10,000 permutations. Permutations were performed
using PLINK to assign random case–control status within each
matched stratum, followed by modeling in SAS as before. The false
discovery rate was calculated to estimate the proportion of
significant findings expected to be false positives.
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